FindTrial
Sign In

Adult patients undergoing Ultrasonography guided block for upper limb surgeries, comparing 20ml 0.5% Levobupivacaine with 90mcg Buprenorphine and 20ml 0.5% Ropivacaine with 90mcg Buprenorphine in the terms of duration of postoperative pain relief.

A Randomised double-blind controlled trial to compare the block efficacy, postoperative analgesia requirements and safety profile between 0.5 percent Ropivacaine with 90mcg Buprenorphine and 0.5 percent Levobupivacaine with 90mcg Buprenorphine in adult patients undergoing upper limb orthopaedic surgeries with ultrasound guided Supraclavicular Brachial Plexus Block anaesthesia - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082476
Enrollment
64
Registered
2025-03-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S52- Fracture of forearm

Interventions

Intervention1: Supraclavicular Brachial Plexus Block using Levobupivacaine: Supraclavicular Brachial Plexus Block will be given to adult patients undergoing upperlimb orthopaedic surgeries using 0.5%

Sponsors

Mahatma Gandhi Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. American society of Anaesthesiologists (ASA) physical status I/II patients 2. Patients weight more than 40 kg 3. Patients scheduled for emergency, semi emergency or elective upper limb orthopaedic upper limb (elbow, forearm and hand) surgery. 4. Patients willing to take part in the study. Haemodynamically stable patient with HR more than 60/min, MAP more than 60mmHg

Exclusion criteria

Exclusion criteria: 1. Patients refusing to voluntarily participate in the study 2. Pre-existing peripheral neuropathy of upper limb 3. Patients with Bleeding disorders 4. Patients with infection at injection site 5. Patients with pneumothorax 6. Patients on adrenoreceptor agonist or antagonist therapy 7. History of severe cardiac disease 8. History of respiratory disease 9. History of hepatic disease / renal disease 10. Pregnancy 11. Known hypersensitivity to the study drugs

Design outcomes

Primary

MeasureTime frame
Time required for first rescue analgesiaTimepoint: 24 hours—

Secondary

MeasureTime frame
Haemodynamic stability, sensory and motor blockTimepoint: 3 hours—

Countries

India

Contacts

Public ContactDr Kabilan R

MAHATMA GANDHI INSTITUTE OF MEDICAL SCIENCES,SEVAGRAM,WARDHA

dhirajbhandari@mgims.ac.in9970195086

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026